An empirical study on growth evaluation of 16 Chinese materia medica listed companies based on factor analysis / 中草药

ABSTRACT

Eight financial indicators of 16 listed companies of Chinese materia medica (CMM) in 2014 were selected by factor analysis method. A comprehensive growth evaluation system was established, so as to make an empirical research on growth evaluation among 16 CMM listed companies. Results show Sixteen CMM listed companies' scale and growth differences among the companies is significant, and overall growth performance should be improved. On the aspect of scale ability, profitability, and growth ability, Jilin Aodong Medicine Industry Group Co., Ltd. (score 29.492), Guangzhou Baiyun Mountain Pharmaceutical Co., Ltd (Baiyun Mountain) (score 31.809), Dongbao Pharmaceutical Co., Ltd. (score 42.110) separately ranked first. The best growth is Baiyun Mountain (score 31.089), and the worst is Taiji Group Co., Ltd. (score -7.053). Some suggestions should be put forward Increase research and investment, enhance innovation, improve the management ability of CMM listed companies; Strengthen the integration of advantageous resources and optimize the structure of products, realizing the scaled and sustained development of CMM listed companies; Establish brand awareness and strengthen internal management, so as to enhance the market competitiveness of CMM listed companies, etc.